Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Pulmonary Or Respiratory Drug Delivery Market Set To Climb From $82.22 Billion In 2026 To $114.23 Billion By 2030
The market size for pulmonary or respiratory drug delivery has demonstrated substantial growth in recent years. It is anticipated to increase from $75.67 billion in 2025 to $82.23 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.7%. Historically, this growth can be ascribed to an escalation in the prevalence of asthma and COPD, the extensive adoption of inhalers, the expansion of respiratory hospitals, advancements in aerosol technologies, and the proliferation of homecare treatments.
The pulmonary or respiratory drug delivery market is set for robust expansion over the next few years, with its size projected to reach $114.23 billion in 2030, growing at a compound annual growth rate (CAGR) of 8.6%. This growth throughout the forecast period is driven by an aging population, increasing exposure to air pollution, the expansion of digital inhalers, broader homecare settings, and the rising prevalence of chronic respiratory conditions. Significant trends anticipated during this period include a greater embrace of inhalation-based drug delivery methods, a surging demand for home-based respiratory therapies, increased adoption of dry powder and metered dose inhalers, an expansion in the management of chronic respiratory diseases, and a heightened focus on user-friendly delivery devices.
Get A Free Sample Report With In-Depth Market Insights:
Pulmonary Or Respiratory Drug Delivery Market Growth Catalysts And Demand Drivers
The rising incidence of pneumonia is anticipated to stimulate expansion within the pulmonary or respiratory drug delivery market in the coming period. Pneumonia, a lung infection, leads to inflammation of the air sacs, potentially filling them with fluid or pus, resulting in symptoms such as coughing, fever, and labored breathing. Several factors contribute to the escalating prevalence of pneumonia, including aging populations, compromised immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery offers assistance to pneumonia sufferers by administering medications, like antibiotics, bronchodilators, or anti-inflammatory agents, directly to the lungs. This method facilitates quicker and more potent treatment, effectively mitigating symptoms, decreasing inflammation, eradicating infections, and enhancing respiratory function, which ultimately supports recovery and avoids complications. As an illustration, data from Clinical Trials Arena, a UK-based clinical research news platform, reported in December 2024 that hospital admissions for Mycoplasma pneumoniae surged by 461% between October 2023 and February 2024, increasing from 110 to 617 admissions. Within this, 20.2% of pneumonia cases were identified in children aged 0 to 4 years, 25.4% in those aged 5 to 9 years, and 17.5% in the 10 to 14 years age bracket, accounting for 410 out of the 650 total reported cases. Consequently, the expanding occurrence of pneumonia acts as a key driver for the pulmonary or respiratory drug delivery market.
Pulmonary Or Respiratory Drug Delivery Market Segmentation And Category Overview
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
Pulmonary Or Respiratory Drug Delivery Market Trends Shaping Long-Term Demand
Leading companies in the pulmonary or respiratory drug delivery market are increasingly focusing on technological breakthroughs, such as intricate drug delivery systems, to boost treatment effectiveness and patient adherence. These advanced drug delivery systems are sophisticated technologies designed to enhance the precise targeting and controlled release of therapeutic substances, thereby improving drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company producing generic and branded medicines, and Kindeva Drug Delivery L.P., a US-based company providing drug delivery services, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol cleared by the Food and Drug Administration, a US-based government agency. This product represents the first generic version of AstraZeneca’s Symbicort and is a metered-dose inhaler that combines budesonide and formoterol for addressing asthma and chronic obstructive pulmonary disease. It is offered in two strengths: 80 micrograms and 160 micrograms, both with 4.5 micrograms of formoterol.
Pulmonary Or Respiratory Drug Delivery Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc
View The Full Pulmonary Or Respiratory Drug Delivery Market Report:
Pulmonary Or Respiratory Drug Delivery Market Geographic Distribution And Regional Opportunities
North America was the largest region in the pulmonary or respiratory drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
